Med Discounts

UroToday.com - Improving bladder capacity and compliance by surgical methods continues to be challenging specially for children and young adults with long life expectancy. Although segments of the digestive tract from stomach to sigmoid colon present satisfactory results in terms of obtaining a compliant reservoir the long-term complications rates are significantly high.

UroToday.com - The tissue ablative techniques for renal tumor management continue to be in their investigational phase. This group highlights the technical limitations associated with cryotherapy of anteriorly located, endophytic tumors. These tumors are often not amenable to percutaneous CT guided cryotherapy and therefore are approached laparoscopically.

UroToday.com- Shimada, et al in the December 2007 of The International Journal of Urology evaluated the surgical treatment for ureterocele with special reference to bladder reconstruction. They reviewed the medical records of 91 children who were diagnosed with a ureterocele and treated. The 91 patients spanned over 14 years.

UroToday.com - This study by Decramer, et al in the October 2007 issue of World Journal of Urology looked at non-invasive markers for ureteropelvic junction obstruction to predict the necessity of pyeloplasty. It evaluated both non-invasive urinary biomarkers for UPJ obstruction as well as proteomics.

UroToday.com - In a report in the January 2008 issue of Qualitative Health Research, an Oxford University team of sociologists led by Alison Chapple analyzed British men’s views and experiences regarding PSA screening.

UroToday.com- Relationship between Endogenous Sex Hormones and Prostate Cancer Not Demonstrated in Prospective Study: Previous epidemiologic studies relating serum hormone levels to prostate cancer (CaP) risk have been inconclusive. In the International Journal of Cancer, Dr.

UroToday.com - A report in the December, 2007 issue of Urology by Dr. Okotie and the group of Dr. William Catalona suggests the digital rectal examination (DRE) remains an important element of prostate cancer (CaP) screening. The group performed the study, as others have suggested that DRE is no longer necessary to CaP screening.

The authors evaluated the role of Celecoxib, an inhibitor of Prostaglandin E(2) (PGE(2)), which is a potent immune modulator in the treatment of urothelial cancer. PGE(2) is known to suppress both tumour antigen-specific helper T (T(H)1) cells and the generation of cytotoxic T lymphocytes (CTLs).

UroToday.com - Despite two decades of experience, the clinical evaluation of the prostate cancer patient in the context of PSA screening remains controversial. Many patients today have a low risk of disease-related mortality, and there is no clear consensus for their optimal treatment or whether they should be treated at all.

UroToday.com - The authors believe that this case series highlights a concern that was once theoretical and now appears real: the ideal screening regimen and the true incidence of malignancy in patients who have undergone bladder augmentation remain unknown.